

The World Health Organization (WHO) has released its recommendations for the composition of influenza vaccines for the southern hemisphere influenza season in 2023. These recommendations are based on data collected by the WHO Global Influenza Surveillance and Response System (GISRS), a network of over 150 laboratories in 127 countries that conducts year-round surveillance of influenza and other respiratory viruses.

The periodic update of viral strains included in influenza vaccines is necessary to ensure their effectiveness, as influenza viruses are constantly evolving. These recommendations will be used by national vaccine regulatory agencies and pharmaceutical companies to develop, produce, and license influenza vaccines for the upcoming season.

According to WHO, around one billion people get seasonal influenza every year, and the threat of an influenza pandemic is always present. Therefore, monitoring circulating respiratory viruses, including influenza, is critical to inform vaccine composition recommendations, which WHO issues twice a year. For the 2023 southern hemisphere influenza season, WHO recommends





that quadrivalent vaccines contain the following:

Egg-based vaccines:

- an A/Sydney/5/2021 (H1N1) pdm09-Like virus;
- an A/Darwin/9/2021 (H3N2)-Like virus;
- a B/Austria/1359417/2021 (B/Victoria Lineage)-Like virus; and
- a B/Phuket/307 3/2013 (B/Yamagata Lineage)-Like virus.

Read the full article and other vaccine compositions recommended by WHO link given in the reference section.

FluQuadri® is an inactivated quadrivalent inactivated influenza vaccine (SPLIT VIRION) I.P. SH- 2023. FluQuadri® is indicated for the prevention of influenza disease caused by influenza types A and B viruses contained in the vaccine.

Each dose of 0.5ml contains:

with other inactive ingredients


Age	Dose	Schedule
6 months through 35 months	One or two doses ^a , 0.5 ml each	If 2 doses, administer at least 4 weeks apart
36 months through 8 years	One or two doses ^a , 0.5 ml each	If 2 doses, administer at least 4 weeks apart
9 years and older	One dose, 0.5ml	-

a 1 or 2 doses depends on vaccination history as per Advisory Committee on Immunization Practices annual recommendations on prevention and control of influenza with vaccines.

(Please refer to PI on <u>www.Sanofi.in</u> if more information is required)







Read the full article and other vaccine compositions recommended by WHO in the link below-

https://www.who.int/news/item/23-09-2022-new-recommendations-for-the-composition-of-influenza-vaccines-in-2023-for-the-southern-hemisphere

Reference: *New recommendations for the composition of influenza vaccines in 2023 for the southern hemisphere https://www.who.int/news/item/23-09-2022-new-recommendations-for-the-composition-of-influenza-vaccines-in-2023-for-the-southern-hemisphere accessed on 18-04-2023

For full prescribing information visit - https://app.hidoc.co/5A87F1

sanofi

Sanofi Healthcare India (P) Ltd.

Sanofi House CTS No. 117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai 400072, Tel No. 022-28032000, Fax: 022-28032939